stockrow
Friday 6 November 2026
Export BLCO’s income statement to Excel — free account
Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
19.94
0.66
−3.20%
Follow BLCO
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.12 | 1.11 | 1.08 | 1.18 | |
P/FCF ratio |
26.78 | 52.80 | 0.00 | 0.00 | |
P/Operating CF |
26.09 | 38.65 | 176.49 | 44.43 | |
P/B ratio |
0.93 | 0.92 | 0.88 | 0.93 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.97 | 2.00 | 2.00 | 2.10 | |
EV/EBITDA |
13.31 | 14.22 | 15.79 | 19.43 | |
EV/Operating CF |
19.24 | 23.25 | 30.70 | 37.91 | |
EV/FCF |
46.96 | 95.09 | (434.94) | (117.89) | |
Quick Ratio |
0.85 | 0.81 | 0.76 | 0.84 | |
Current Ratio |
1.56 | 1.55 | 1.53 | 1.55 | |
Net Debt/EBITDA |
17.62 | 25.06 | 34.97 | 21.79 | |
Debt/Assets |
36.50% | 36.91% | 36.79% | 36.24% | |
Debt/Equity |
0.78 | 0.79 | 0.79 | 0.78 | |
Asset Turnover |
0.39 | 0.38 | 0.38 | 0.37 | |
Operating CF/Net income |
7.28 | (10.93) | (0.45) | (2.34) | |
Capex/Depreciation |
(0.52) | (0.67) | (0.96) | (0.74) | |
Interest Coverage |
1.63 | 0.89 | 0.34 | 1.14 | |
Research and Development Expense of Revenue |
6.62% | 8.18% | 8.12% | 6.69% | |
Selling, General and Administrative Expense of Revenue |
40.44% | 42.18% | 43.73% | 40.14% | |
Intangible Assets out of Total Assets |
0.56 | 0.57 | 0.58 | 0.57 | |
Share Based Compensation of Revenue |
2.69% | 2.73% | 2.73% | 4.56% | |
Graham Net Nets |
(0.72) | (0.76) | (0.81) | (0.75) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.78%) | (2.90%) | (3.90%) | (5.97%) | |
Free Cash Flow Yield |
3.73% | 1.89% | (0.42%) | (1.51%) | |
Revenue per Share |
3.85 | 3.90 | 3.50 | 3.97 | |
Operating CF per Share |
0.65 | 0.43 | 0.09 | 0.38 | |
Capex per Share |
(0.15) | (0.20) | (0.28) | (0.21) | |
Free Cash Flow per Share |
0.50 | 0.23 | (0.19) | 0.17 | |
Cash per Share |
1.44 | 1.06 | 0.79 | 1.12 | |
Shareholders Equity per Share |
18.20 | 18.05 | 18.16 | 18.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.20 | 18.05 | 18.16 | 18.43 | |
Free Cash Flow |
178.00 | 82.00 | (68.00) | 60.00 | |
Working Capital |
1,095.00 | 1,032.00 | 956.00 | 1,057.00 | |
Capital Expenditures |
(55.00) | (71.00) | (100.00) | (76.00) | |
Net Current Asset Value |
(4,394.00) | (4,493.00) | (4,552.00) | (4,526.00) | |
EV/EBIT |
27.83 | 32.97 | 45.58 | 94.94 | |
Capex to Sales |
0.04 | 0.05 | 0.08 | 0.05 | |
Price to Operating Income |
15.87 | 18.31 | 24.66 | 53.48 | |
| Other line items | |||||
Average Receivables |
1,118.00 | 1,122.00 | 1,056.50 | 1,123.50 | |
Average Payables |
381.00 | 437.50 | 417.00 | 388.50 | |
Average Inventory |
1,006.00 | 1,025.00 | 1,004.00 | 1,006.00 | |
Average Assets |
13,895.50 | 13,845.50 | 13,604.00 | 13,745.50 | |
Average Common Equity |
6,505.00 | 6,476.00 | 6,442.50 | 6,531.50 |
Columns are period end dates · fundamentals updated 2 Nov 2026